116 related articles for article (PubMed ID: 34886751)
41. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
42. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
Lavoie JC; Connors JM; Phillips GL; Reece DE; Barnett MJ; Forrest DL; Gascoyne RD; Hogge DE; Nantel SH; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Voss NJ; Nevill TJ
Blood; 2005 Aug; 106(4):1473-8. PubMed ID: 15870180
[TBL] [Abstract][Full Text] [Related]
43. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Khan N; Moskowitz AJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
[TBL] [Abstract][Full Text] [Related]
44. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
45. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
46. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
[TBL] [Abstract][Full Text] [Related]
47. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Martínez C; Díaz-López A; Rodriguez-Calvillo M; García-Sanz R; Terol MJ; Pérez-Ceballos E; Jiménez MJ; Cantalapiedra A; Domingo-Domenech E; Rodriguez MJ; Sampol A; Espeso M; López FJ; Briones J; García JF; Sureda A;
Br J Haematol; 2016 Sep; 174(6):859-67. PubMed ID: 27185197
[TBL] [Abstract][Full Text] [Related]
49. Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation.
Blum KA
Cancer J; 2018; 24(5):244-248. PubMed ID: 30247260
[TBL] [Abstract][Full Text] [Related]
50. Optimal treatment for relapsing patients with Hodgkin lymphoma.
Sibon D; Brice P
Expert Rev Hematol; 2009 Jun; 2(3):285-95. PubMed ID: 21082970
[TBL] [Abstract][Full Text] [Related]
51. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.
David KA; Mauro L; Evens AM
Curr Treat Options Oncol; 2007 Oct; 8(5):352-74. PubMed ID: 18214690
[TBL] [Abstract][Full Text] [Related]
52. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
Gopal AK; Metcalfe TL; Gooley TA; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg L; Maloney DG; Press OW
Cancer; 2008 Sep; 113(6):1344-50. PubMed ID: 18623377
[TBL] [Abstract][Full Text] [Related]
53. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
Friend BD; Muhsen IN; Patel S; Hill LC; Lulla P; Ramos CA; Pingali SR; Kamble RT; John TD; Salem B; Bhar S; Doherty EE; Craddock J; Sasa G; Wu M; Wang T; Martinez C; Krance RA; Heslop HE; Carrum G
Bone Marrow Transplant; 2022 Apr; 57(4):579-585. PubMed ID: 35105965
[TBL] [Abstract][Full Text] [Related]
54. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
55. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
[TBL] [Abstract][Full Text] [Related]
56. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
57. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
Moskowitz CH; Yahalom J; Zelenetz AD; Zhang Z; Filippa D; Teruya-Feldstein J; Kewalramani T; Moskowitz AJ; Rice RD; Maragulia J; Vanak J; Trippett T; Hamlin P; Horowitz S; Noy A; O'Connor OA; Portlock C; Straus D; Nimer SD
Br J Haematol; 2010 Mar; 148(6):890-7. PubMed ID: 20085577
[TBL] [Abstract][Full Text] [Related]
58.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
59. Immunodeficiency-associated Hodgkin lymphoma.
Carbone A; Gloghini A; Serraino D; Spina M; Tirelli U; Vaccher E
Expert Rev Hematol; 2021 Jun; 14(6):547-559. PubMed ID: 34044724
[No Abstract] [Full Text] [Related]
60. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
